SGP

+ Watchlist + Portfolio

SpyGlass Pharma, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $27.23
52-Week Range: $17.06 – $32.44
Market Cap: $877.34M
P/E (TTM): —
EPS (TTM): -1.68
Dividend Yield: —

Advanced Metrics

Price/Book: 3.51
PEG Ratio: —
Return on Equity: —
Return on Assets: —
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 25.06
Debt/Equity: 0.01
Total Debt: $1.63M
Free Cash Flow: —
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $678.23M

SGP Income statement, annual periods, in USD
USD	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00
Research & Development	$9.96M	$19.98M	$29.18M
Selling, General & Admin	$4.27M	$7.08M	$12.27M
Operating Expenses	$14.23M	$27.06M	$41.45M
Operating Income	-$14.23M	-$27.06M	-$41.45M
EBITDA	-$14.11M	-$26.79M	-$40.84M
Pretax Income	-$13.32M	-$29.16M	-$39.87M
Income Tax	$0.00	$0.00	$0.00
Net Income	-$13.32M	-$29.16M	-$39.87M
Diluted EPS	-1.17	-1.62	-1.25
Diluted Shares	11.40M	17.96M	31.91M

SGP Balance Sheet statement, annual periods, in USD
USD	FY2023	FY2024	FY2025
Cash & Equivalents	$15.85M	$16.27M	$96.36M
Receivables	$122.91K	$423.00K	$431.00K
Current Assets	$40.61M	$17.41M	$108.77M
Total Assets	$41.15M	$23.32M	$115.87M
Current Liabilities	$1.59M	$7.79M	$8.58M
Total Debt	$0.00	$3.90M	$1.58M
Total Liabilities	$74.13M	$83.79M	$214.70M
Retained Earnings	-$35.70M	-$64.86M	-$104.73M
Shareholders' Equity	-$32.99M	-$60.47M	-$98.84M
Working Capital	$39.03M	$9.62M	$100.18M

SGP Cash Flow statement, annual periods, in USD
USD	FY2023	FY2024	FY2025
Operating Cash Flow	-$12.28M	-$22.03M	-$32.70M
Capital Expenditure	-$216.54K	-$1.99M	-$789.00K
Free Cash Flow	-$12.49M	-$24.02M	-$33.49M
Depreciation & Amortisation	$122.67K	$271.00K	$612.00K
Stock-Based Compensation	$874.20K	$1.49M	$2.79M
Investing Cash Flow	-$20.49M	$22.26M	-$11.79M
Financing Cash Flow	$39.77M	$185.00K	$124.58M
Share Repurchases	—	$0.00	-$1.45M
Net Change in Cash	$7.01M	$419.00K	$80.09M

SGP Income statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$5.74M	$6.05M	$7.71M	$8.54M
Selling, General & Admin	$2.01M	$1.37M	$5.92M	$6.87M
Operating Expenses	$7.75M	$7.42M	$13.63M	$15.41M
Operating Income	-$7.75M	-$7.42M	-$13.63M	-$15.41M
EBITDA	-$7.65M	-$7.30M	-$13.41M	-$15.09M
Pretax Income	-$8.40M	-$8.82M	-$12.56M	-$13.82M
Income Tax	$0.00	$0.00	$0.00	$0.00
Net Income	-$8.40M	-$8.82M	-$12.56M	-$13.82M
Diluted EPS	—	-0.49	—	-0.69
Diluted Shares	—	17.96M	—	19.93M

SGP Balance Sheet statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q4 2025	Q1 2026
Cash & Equivalents	$16.27M	$106.01M	$96.36M	$238.90M
Receivables	$423.00K	$418.01K	$431.00K	$653.00K
Current Assets	$17.41M	$119.70M	$108.77M	$253.36M
Total Assets	$23.32M	$127.01M	$115.87M	$258.39M
Current Liabilities	$7.79M	$6.61M	$8.58M	$6.67M
Total Debt	$3.90M	$3.57M	$1.58M	$1.61M
Total Liabilities	$83.79M	$214.24M	$214.70M	$8.27M
Retained Earnings	-$64.86M	-$92.18M	-$104.73M	-$118.55M
Shareholders' Equity	-$60.47M	-$87.22M	-$98.84M	$250.11M
Working Capital	$9.62M	$113.09M	$100.18M	$246.69M

SGP Cash Flow statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$6.25M	-$8.20M	-$9.33M	-$13.54M
Capital Expenditure	-$438.97K	-$164.00K	-$420.49K	-$676.00K
Free Cash Flow	-$6.69M	-$8.37M	-$9.75M	-$14.22M
Depreciation & Amortisation	$107.90K	$124.00K	$216.73K	$318.00K
Stock-Based Compensation	$407.62K	$345.00K	$922.25K	$1.68M
Investing Cash Flow	$4.04M	-$164.00K	$574.70K	-$1.67M
Financing Cash Flow	$142.57K	$50.10M	-$889.64K	$157.75M
Share Repurchases	—	—	$0.00	—
Net Change in Cash	-$2.06M	$41.73M	-$9.65M	$142.54M

Market Snapshot

About

SpyGlass Pharma, Inc. is a biopharmaceutical company developing treatments for gastrointestinal diseases. The company focuses on novel therapeutic candidates for conditions affecting the digestive system. SpyGlass is working to advance its pipeline through clinical development.